Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report

European Journal of Cancer

Volumn 39, Issue 1, 2003, Pages 70-77

  Marchand, Marie ^a,b,k   Punt, C J A ^c   Aamdal, S ^d   Escudier, B ^e   Kruit, W H J ^f   Keilholz, U ^g   Hakansson L ^h   Van Baren, N ^a,b   Humblet, Y ^b   Mulders, P ^c   Avril, M F ^e   Eggermont, A M M ^f   Scheibenbogen, C ^g   Uiters, J ⁱ   Wanders, J ⁱ   Delire, M ^j   Boon, T ^a   Stoter, G ^f  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f ERASMUS MC CANCER INSTITUTE   (Netherlands)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

ⁱ NDDO Oncology   (Netherlands)

^j GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^k NONE   (Belgium)

more..

Author keywords

Antibodies; Cancer; Immunological adjuvant SBAS 2; Immunotherapy; MAGE 3 protein; Melanoma; T lymphocyte

Indexed keywords

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; MELANOMA ANTIGEN 3; PHOSPHORYL LIPID A; QS 21; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER METASTASIS; CANCER GROWTH; CANCER IMMUNIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG RESPONSE; DRUG TOLERABILITY; ESCHERICHIA COLI; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VISCERAL METASTASIS;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNIZATION; LIPID A; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; RECOMBINANT PROTEINS; SAPONINS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 0037215111     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00479-3     Document Type: Article

References (21)

1. van der Bruggen P., Traversari C., Chomez P.et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647.
2. Van den Eynde B.J., van der Bruggen P. T cell defined tumour antigens. Curr Opin Immunol. 9:1997;684-693.
3. Marchand M., Weynants P., Rankin E.et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer. 63:1995;883-885.
4. Marchand M., van Baren N., Weynants P.et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 80:1999;219-230.
5. Marchand M., Brichard V., van Baren N., Coulie P.G. Biological and clinical developments in melanoma vaccines. Expert Opin Biol Ther. 1:2001;497-510.
6. Chaux P., Luiten R., Demotte N.et al. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol. 163:1999;2928-2936.
7. Gérard C.M., Baudson N., Kraemer K.et al. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine. 19:2001;2583-2589.
8. Stoute J.A., Slaoui M., Heppner D.G.et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med. 336:1997;86-91.
9. Beahrs O., Henson D., Hutter R.et al. American Joint Committee on Cancer. Manual for Staging of Cancer. 4th edn:1992;J.B. Lippincott, Philadelphia.
10. National Cancer Institute of Canada Clinical Trial Group (Revised version December 1994). Recommendations for Grading of Acute and Subacute Toxicity.
11. WHO, Handbook for Reporting Results of Cancer Treatment. Geneva (Switzerland), World Health Organization Offset, Publication No. 48, 1979.
12. Miller A.B., Hogestraeten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
13. Guilloux Y., Lucas S., Brichard V.G.et al. A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med. 183:1996;1173-1183.
14. Brichard V.G., Dorval T., Salmon R.J.et al. Peptide-based immunization against tumor-specific antigen NA17.A2 in HLA-A2 patients with metastatic cutaneous or ocular melanoma. Proc Am Ass Cancer Res. 42:2001;699. (abstract).
15. Weber J.S., Hua F.L., Spears L., Marty V., Kuniyoshi C., Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother. 22:1999;431-440.
16. Nestle F.O., Alijagic S., Gilliet M.et al. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nat Med. 4:1998;328-332.
17. Thurner B., Haendle I., Röder C.et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 190:1999;1669-1678.
18. Schuler-Thurner B., Dieckmann D., Keikavoussi P.et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol. 165:2000;3492-3496.
19. Toungouz M., Libin M., Bulté F.et al. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with Mage-A1/A3-positive tumors. J Leukoc Biol. 69:2001;937-943.
20. Jäger E., Gnjatic S., Nagata Y.et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA. 97:2000;12198-12203.
21. Nishiyama T., Tachibana M., Horiguchi Y.et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res. 7:2001;23-31.